The Contemporary Role of Hematopoietic Stem Cell Transplantation in the Management of Chronic Myeloid Leukemia: Is It the Same in All Settings?
- PMID: 38398145
- PMCID: PMC10886670
- DOI: 10.3390/cancers16040754
The Contemporary Role of Hematopoietic Stem Cell Transplantation in the Management of Chronic Myeloid Leukemia: Is It the Same in All Settings?
Abstract
Hematopoietic stem cell transplantation (HSCT) for chronic myeloid leukemia (CML) patients has transitioned from the standard of care to a treatment option limited to those with unsatisfactory tyrosine kinase inhibitor (TKI) responses and advanced disease stages. In recent years, the threshold for undergoing HSCT has increased. Most CML patients now have life expectancies comparable to the general population, and therefore, the goal of therapy is shifting toward achieving treatment-free remission (TFR). While TKI discontinuation trials in CML show potential for achieving TFR, relapse risk is high, affirming allogeneic HSCT as the sole curative treatment. HSCT should be incorporated into treatment algorithms from the time of diagnosis and, in some patients, evaluated as soon as possible. In this review, we will look at some of the recent advances in HSCT, as well as its indication in the era of aiming for TFR in the presence of TKIs in CML.
Keywords: BCR–ABL1 gene fusion; chronic myeloid leukemia; hematopoietic stem cell transplant; survival; treatment-free remission; tyrosine kinase inhibitors.
Conflict of interest statement
The authors declare that they have no known competing financial interest or personal relationship that could have appeared to influence the work reported in this paper.
Similar articles
-
Transplant to treatment-free remission: the evolving view of 'cure' in chronic myeloid leukemia.Expert Rev Hematol. 2015 Dec;8(6):785-97. doi: 10.1586/17474086.2015.1087843. Epub 2015 Sep 12. Expert Rev Hematol. 2015. PMID: 26364871 Review.
-
Allogeneic Transplantation in Chronic Myeloid Leukemia and the Effect of Tyrosine Kinase Inhibitors on Survival: A Quasi-Experimental Study.Turk J Haematol. 2017 Mar 1;34(1):16-26. doi: 10.4274/tjh.2015.0346. Epub 2016 Apr 18. Turk J Haematol. 2017. PMID: 27094579 Free PMC article.
-
Patients with Philadelphia-positive leukemia with BCR-ABL kinase mutations before allogeneic transplantation predominantly relapse with the same mutation.Biol Blood Marrow Transplant. 2015 Jan;21(1):184-9. doi: 10.1016/j.bbmt.2014.09.012. Epub 2014 Oct 6. Biol Blood Marrow Transplant. 2015. PMID: 25300870 Free PMC article.
-
Discontinuation of Maintenance Tyrosine Kinase Inhibitors in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia outside of Transplant.Acta Haematol. 2021;144(3):285-292. doi: 10.1159/000510112. Epub 2020 Nov 25. Acta Haematol. 2021. PMID: 33238261
-
Chronic Myeloid Leukemia: Modern therapies, current challenges and future directions.Blood Rev. 2021 Sep;49:100825. doi: 10.1016/j.blre.2021.100825. Epub 2021 Mar 16. Blood Rev. 2021. PMID: 33773846 Free PMC article. Review.
Cited by
-
Next-generation immunotherapeutic approaches for blood cancers: Exploring the efficacy of CAR-T and cancer vaccines.Exp Hematol Oncol. 2025 May 17;14(1):75. doi: 10.1186/s40164-025-00662-3. Exp Hematol Oncol. 2025. PMID: 40382583 Free PMC article. Review.
-
Dual targeting of CXC chemokine receptor 4 and multidrug resistance protein 1 by ZIN056 effectively combat daunorubicin resistance in acute myeloid leukemia cells.Med Oncol. 2025 Mar 13;42(4):106. doi: 10.1007/s12032-025-02656-x. Med Oncol. 2025. PMID: 40080290
-
Assessing the visibility and public engagement of bone marrow and stem cell transplantation research: An altmetric analysis.Heliyon. 2025 Jan 17;11(3):e41954. doi: 10.1016/j.heliyon.2025.e41954. eCollection 2025 Feb 15. Heliyon. 2025. PMID: 39959495 Free PMC article.
-
Desensitization Strategies for Donor-Specific Antibodies in HLA-Mismatched Stem Cell Transplantation Recipients: What We Know and What We Do Not Know.Oncol Ther. 2024 Sep;12(3):375-394. doi: 10.1007/s40487-024-00283-6. Epub 2024 Jun 15. Oncol Ther. 2024. PMID: 38879734 Free PMC article. Review.
References
-
- Onida F., Ball G., Kantarjian H.M., Smith T.L., Glassman A., Albitar M., Scappini B., Rios M.B., Keating M.J., Beran M. Characteristics and outcome of patients with Philadelphia chromosome negative, bcr/abl negative chronic myelogenous leukemia. Cancer. 2002;95:1673–1684. doi: 10.1002/cncr.10832. - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous